Screener
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:21 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001100682-26-000118
| Capital Expenditures / Three Months Ended: | RMS | DSA | Manufacturing | Unallocated Corporate | Consolidated |
|---|---|---|---|---|---|
| June 28, 2025 | 10,926 | 53,021 | 28,440 | 2,235 | 94,622 |
| Depreciation and amortization (1) | |||||
| Three Months Ended: | |||||
| June 27, 2026 | $15,733 | $41,633 | $7,389 | $2,535 | $67,290 |
| June 28, 2025 | 19,710 | 42,575 | 55,343 | 1,879 | 119,507 |
| Six Months Ended: | |||||
| June 27, 2026 | $31,873 | $81,547 | $15,788 | $5,233 | $134,441 |
| June 28, 2025 | 41,471 | 84,659 | 109,966 | 3,775 | 239,871 |
Item 1. Financial Statements
FAQ
- What is Charles River Laboratories's D&A?
- Charles River Laboratories (CRL) reported D&A of $67.29M in Q2 2026.
- How has Charles River Laboratories's D&A changed year-over-year?
- Charles River Laboratories's D&A decreased by 43.7% year-over-year, from $119.51M to $67.29M.
- What is the long-term trend for Charles River Laboratories's D&A?
- Over 4 years (2021 to 2025), Charles River Laboratories's D&A has grown at a 11.0% compound annual growth rate (CAGR), from $265.54M to $403.31M.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about Charles River Laboratories's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude